MDV-3100 is an oral, daily drug that is used after someone
no longer responds to taxotere chemotherapy. It should be
available through an early access program (EAP) in the spring.
Alpharadin is an IV radiopharmaceutical drug (given every
4 weeks) that also should be available in the spring, which
helps men with bone pain from HRPC and also improves
survival. Alpharadin is arguably less well known right now
compared to MDV3100 so, if you want to see a really good
video about how Alpharadin works go to www.algeta.no/dynside.asp?m=34568&s=34659 , scroll down and click
on the “see video on ALSYMPCA clinical trial for bone
metastases in CRPC patients.” Please keep in mind that this
video was made before the results of their successful phase 3
trial (no big deal - still very informative).
======================================================
(some people getting it through clinical trials now also, guessing approval is coming eventually and maybe soon)
MORE INFO weblink Dr. Sawyers http://pharmastrategyblog.com/2011/05making-a-difference
Medscape: www.medscape.com/viewarticle/720292
(do google searches for more on this)